Fighting Virus Pandemics: The Now and The Future - Expert’s Perception of Challenges & Opportunities

Feb 13 2020

 
 

Moderator:

Invited guest:

About Atriva

Based in a beautiful university town Tübingen in Germany, Atriva is a biotech company that is developing a promising therapy targeting Influenza and other viruses which may include the Coronavirus.

Recap

Having traveled to China twice during the past year for scientific and partnering conferences, Dr. Lichtenberger has a deep impression on the quality and wealth of research development in China. Regarding treatment development timeline for the current coronavirus pandemic in China, Dr. Lichtenberger is optimistic about the world’s joint efforts but sees the general situation as not well-prepared given virus researches have been mostly targeted and specifically designed for existing virus strains. As R&D mode started to change over the past 2-3 years, a focus is to develop immediate counter weapon against such pandemic attacks, and Atriva is among the first to offer such weapons.

Atriva’s technology is especially suited for severe respiratory infections caused by RNA viruses, such as Flu Virus, Dengue, Chikungunya and Ebola. The company currently focuses on influenza as it is a real health threat which caused ~8000 deaths in US alone in 2019 and ~15M hospitalization in the developed world.

Atriva is the first in successfully targeting structures in the host cell instead of targeting viral structures, and has found many global and regional interests for partnership, especially in the face of the coronavirus outbreak. All management members have over 20 years of leadership experiences in life sciences.